GDx Staging System is successful in RNFL damage classification

Article

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage.

The GDx Staging System is an efficient way to interpret retinal fibre layer (RNFL) damage, according to a study published in the Journal of Glaucoma.

Dr Paolo Brusini et al., Department of Ophthalmology, Azienda Ospedaliero-Universitaria, Udine, Italy, conducted 320 GDx VCC tests on 84 healthy patients and 236 patients suffering from ocular hypertension or chronic open angle glaucoma. Additionally, the sensitivity and specificity of the GDx was measured in 161 patients with ocular hypertension or chronic open angle glaucoma and 34 normal patients.

The findings showed that sensitivity and the specificity of the GDx were significantly high at 88.2% and 100%, respectively. The results of clinical classification of glaucoma and the Glaucoma Staging System 2 were strongly correlated.

The GDx Staging System is a quick and effective method for classifying RNFL damage, especially for inexperienced ophthalmologists.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.